Belgium may be a relatively small pharmaceutical market in size, but it is disproportionately influential in terms of expertise, clinical research activity and medical thought leadership. Its dense hospital network, internationally recognized academic centers and multilingual structure create a uniquely strategic environment for organizing HCP advisory boards.
Yet many advisory boards organized in Belgium still underperform. They generate interesting discussions but limited implementation. The difference between a routine meeting and a high-impact advisory board lies in preparation, participant selection, regulatory rigor and, most importantly, post-meeting execution.
If you are planning to organize an HCP advisory board in Belgium, this guide outlines the strategic elements that determine real impact.
Define a clear strategic objective
One of the most common mistakes in organizing an HCP advisory board is starting with operational questions such as venue, date or speaker slides. In Belgium’s highly structured healthcare environment, advisory boards must be strategically anchored from the outset.
Before sending invitations, clarify the core objective.
Is the advisory board meant to validate a pre-launch positioning?
Refine a reimbursement narrative?
Explore barriers to adoption in real-world practice?
Strengthen a Phase IV or real-world evidence program?
Or optimize an existing patient support program?
Belgian stakeholders expect precision and scientific clarity. An advisory board without defined objectives risks becoming an open discussion with limited actionable output. Defining two or three measurable outcomes in advance significantly increases the likelihood that insights will translate into operational decisions.
Start with strategy,
not logistics
One of the most common mistakes in organizing an HCP advisory board is starting with operational questions such as venue, date or speaker slides. In Belgium’s highly structured healthcare environment, advisory boards must be strategically anchored from the outset.
Before sending invitations, clarify the core objective. Is the advisory board meant to validate a pre-launch positioning? Refine a reimbursement narrative? Explore barriers to adoption in real-world practice? Strengthen a Phase IV or real-world evidence program? Or optimize an existing patient support program?
Belgian stakeholders expect precision and scientific clarity. An advisory board without defined objectives risks becoming an open discussion with limited actionable output. Defining two or three measurable outcomes in advance significantly increases the likelihood that insights will translate into operational decisions.
Understand the specificities of the Belgian healthcare landscape
Organizing an HCP advisory board in Belgium requires a nuanced understanding of its healthcare structure.
Belgium is strongly hospital-driven, with influential academic centers in Leuven, Ghent, Brussels, Antwerp and Liège. At the same time, regional dynamics and prescribing behaviors vary between Flanders and Wallonia. Reimbursement pathways can be complex, and hospital formularies play a critical role in access.
An effective advisory board therefore requires a balanced representation. Academic key opinion leaders bring scientific credibility and guideline insight. Regional hospital specialists contribute practical experience. Community-based prescribers provide perspective on treatment adoption outside reference centers. In certain therapeutic areas, hospital pharmacists and specialized nurses add operational depth.
Limiting participation to high-profile academic KOLs may enhance prestige but can reduce real-world relevance. A carefully curated mix produces richer and more implementable insights.
Leverage Belgium's multilingual and cross-border advantage
Belgium offers a structural advantage that is often underestimated: its multilingual environment.
Advisory boards can be organized in French or Dutch, allowing participants to express themselves in their native language. This significantly improves the depth and authenticity of discussions. In some cases, bilingual formats can be considered, depending on objectives and group composition.
This linguistic flexibility becomes particularly powerful in rare diseases. In ultra-specialized therapeutic areas, Belgium’s central geographical position allows participation from border regions in France and the Netherlands. French-speaking specialists from northern France or Dutch-speaking experts from the southern Netherlands can easily attend Belgian sessions.
For rare disease advisory boards, where the number of experts is limited, this cross-border accessibility expands the pool of expertise while maintaining manageable logistics. Few European markets offer this combination of linguistic segmentation and geographic centrality.
Ensure full compliance with Belgian transparency
and industry regulations
Belgium maintains strict compliance standards aligned with EFPIA principles and local transparency requirements. Organizing an HCP advisory board requires careful attention to fair market value compensation, documented scientific rationale and contractual transparency.
Hospitality must remain proportionate and secondary to the scientific objective. Disclosure obligations must be anticipated and managed appropriately. Non-compliance not only creates legal risk but can undermine long-term credibility with healthcare professionals.
A robust compliance framework is not an administrative burden. It is a prerequisite for building trust and sustaining engagement in a relatively compact market where professional networks are closely interconnected.
Design an agenda that drives insight,
not presentation
Belgian healthcare professionals value scientific rigor and efficient use of time. An effective advisory board should minimize passive listening and maximize structured interaction.
The session should begin with a clear framing of objectives and a concise scientific context setting. This is not the place for extensive promotional content. The core of the meeting must focus on moderated discussion, guided by precise and well-prepared questions.
Interactive methods such as structured case discussions, breakout groups or digital polling tools can help transform qualitative feedback into semi-quantifiable insights. Prioritization exercises, where participants rank barriers or strategic options, significantly enhance post-meeting usability.
An advisory board that ends with a validated synthesis of key insights ensures alignment and reduces ambiguity during implementation.
Translate insights
into measurable action
The real value of an HCP advisory board in Belgium is not measured during the session itself but in the weeks that follow.
Within 48 to 72 hours, insights should be clustered thematically and evaluated based on impact and feasibility. Cross-functional teams, including medical affairs, market access and commercial strategy where appropriate, should align on actionable next steps.
In a market the size of Belgium, speed of implementation can become a competitive advantage. Rapid adaptation of messaging, refinement of educational tools or adjustment of patient support initiatives can create tangible differentiation.
When appropriate, closing the feedback loop with participating HCPs reinforces long-term relationships and demonstrates that their expertise has influenced strategic decisions.
Common pitfalls to avoid
Even experienced teams can misjudge certain aspects of advisory board organization in Belgium. Over-reliance on academic KOLs, insufficient linguistic consideration, unclear objectives or inadequate follow-up are frequent causes of underperformance.
Another recurring mistake is confusing advisory boards with promotional events. In Belgium’s compliance-sensitive environment, scientific credibility must remain central.
Conclusion
Organizing an HCP advisory board in Belgium offers significant strategic potential when approached thoughtfully. The country’s multilingual structure, strong academic ecosystem and cross-border accessibility create opportunities that extend beyond its geographical size, particularly in rare diseases and highly specialized therapeutic areas.
When built on clear objectives, balanced participant selection, regulatory rigor and disciplined follow-up, an advisory board becomes more than a discussion forum. It becomes a lever for improving launch readiness, strengthening reimbursement strategy and optimizing patient-centric initiatives.
For pharmaceutical companies operating in Belgium, the question is not whether to organize an advisory board. It is whether to structure it in a way that generates measurable impact.